Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: GENFIT

Market Cap 531M 609M 491M 460M 861M 57.43B 868M 5.83B 2.26B 28.27B 2.28B 2.24B 98.2B P/E 2025
-3.06x
P/E 2026 * 56.1x
Enterprise Value 476M 546M 440M 413M 772M 51.51B 778M 5.23B 2.03B 25.35B 2.05B 2.01B 88.08B EV / Sales 2025
2.34x
EV / Sales 2026 * 5.08x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.28%-.--% - - 593M
+1.44%+1.36%-10.88%-12.14% 42.75B
+3.31%+9.22%+308.19%+562.02% 34.65B
+2.84%+3.80%+6.87%+34.93% 30.03B
-1.70%-7.34%+8.51%-22.34% 28B
-1.90%+2.47%+10.18%+18.13% 24.83B
-0.14%+7.06% - - 14.34B
+0.68%-3.13%+52.04%+107.47% 13.14B
-0.57%-2.83%+3.34%+1.66% 12.61B
-0.26%+0.41%+100.27%+80.69% 12.25B
Average +0.04%+0.55%+59.81%+96.30% 23.62B
Weighted average by Cap. +0.76%+0.91%+64.89%+112.23%

Financials

2025 2026 *
Net sales 66.82M 76.62M 61.82M 57.91M 108M 7.23B 109M 734M 284M 3.56B 288M 281M 12.36B 95.2M 109M 88.08M 82.5M 154M 10.3B 156M 1.05B 405M 5.07B 410M 401M 17.61B
Net income -8.3M -9.52M -7.68M -7.2M -13.47M -898M -13.57M -91.26M -35.33M -442M -35.73M -34.96M -1.54B 18.31M 20.99M 16.94M 15.86M 29.7M 1.98B 29.93M 201M 77.91M 975M 78.79M 77.1M 3.39B
Net Debt -54.72M -62.75M -50.63M -47.42M -88.79M -5.92B -89.46M -602M -233M -2.91B -236M -230M -10.12B -46.87M -53.75M -43.36M -40.62M -76.04M -5.07B -76.62M -515M -199M -2.5B -202M -197M -8.67B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!